In this article
FDA Approval for Pembrolizumab in NSCLC Treatment
Feb 2023: For stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) as adjuvant therapy after resection and platinum-based chemotherapy (NSCLC).
KEYNOTE-091 (NCT02504372), a multicenter, randomised, triple-blind, placebo-controlled trial, assessed efficacy. Patients had not undergone chemotherapy or neoadjuvant radiation. Every three weeks for up to a year, patients were randomised (1:1) to receive either pembrolizumab 200 mg or a placebo intravenously. The location of the world and adjuvant chemotherapy were stratification variables. 1010 (86%) of the 1177 randomised patients who underwent full resection also underwent adjuvant platinum-based treatment.
Disease-free survival, as determined by the investigator, was the primary effectiveness outcome measure (DFS). The trial’s primary goal was met when it showed a statistically significant increase in DFS across the board. The DFS hazard ratio was 1.25 (95% CI: 0.76, 2.05) in an exploratory subgroup analysis of the 167 patients who did not receive adjuvant treatment. The median DFS for patients who had adjuvant chemotherapy was 34.9 months in the pembrolizumab arm (95% CI: 28.6, not reached) and 58.7 months in the pembrolizumab arm (95% CI: 39.2, not reached).
Side Effects and Recommended Dosage
Except for hypothyroidism (22%), hyperthyroidism (11%), and pneumonitis (7%), the adverse events seen in KEYNOTE-091 were mainly similar to those seen in other patients with NSCLC receiving KEYTRUDA as a single drug. There were two fatal myocarditis adverse reactions.
The suggested dose of pembrolizumab is 200 mg every three weeks or 400 mg every six weeks, up to a maximum of 12 months, or until the disease recurs or there is intolerable toxicity.
Project Orbis, an initiative of the FDA Oncology Center of Excellence, was used to carry out this review. International partners can simultaneously submit and review oncology medications using the infrastructure provided by Project Orbis. FDA worked together on this review with the Therapeutic Goods Administration (TGA) of Australia, Health Canada, and Swissmedic. At the other regulatory organizations, the application reviews are still proceeding.
View full prescribing information for Keytruda.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Related Articles
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.